loracarbef

Loracarbef is a synthetic oral beta-lactam antibiotic of the carbacephem class, structurally related to second-generation cephalosporins but with a methylene group replacing the sulfur atom in the dihydrothiazine ring. This modification confers greater chemical stability compared to cefaclor. It acts by inhibiting penicillin-binding proteins (PBPs), which are enzymes involved in bacterial cell wall synthesis, leading to cell lysis and death. Loracarbef was used for treating a broad range of infections caused by both gram-positive and gram-negative bacteria, including upper and lower respiratory tract infections (such as bronchitis, pneumonia, sinusitis, pharyngitis/tonsillitis), skin and soft tissue infections, urinary tract infections (including cystitis and pyelonephritis), impetigo, bladder infection, kidney infection, and middle ear infections. It was well absorbed orally with plasma concentrations exceeding minimum inhibitory concentrations for most target pathogens[1][2][3][4][5][6]. The drug received FDA approval in 1991 under the brand name Lorabid but has since been discontinued from marketing[8].

Brand names

LorabidLorabid Pulvules

Other names

loracarbefumloracarbef anhydrousanhydrous loracarbefLorbefLorafemLoribidCarbac